PCM
VTGN icon

Pinz Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

Pinz Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-633
Closed -$17K – 170
2022
Q2 		$17K Buy
+633
New +$22.4K 0.01% 216

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pinz Capital Management's VTGN Position: Q3 2022 in Review

Pinz Capital Management sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 633 shares — an estimated $17K sold.

Pinz Capital Management first reported a position in VTGN in Q2 2022 and held it in 1 quarter. The position peaked at $17K in Q2 2022. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • Pinz Capital Management reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Pinz Capital Management sold 633 VistaGen Therapeutics shares in Q3 2022, an estimated $17K.
  • Pinz Capital Management first reported a position in VistaGen Therapeutics in Q2 2022 and held it in 1 quarter.
  • Pinz Capital Management's VistaGen Therapeutics position peaked at $17K in Q2 2022.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on Pinz Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.